An interventional study of High-Resolution peripheral Quantitative Computed Tomography Imaging in Rheumatoid Arthritis (RA), Calcium Pyrophosphate Deposition Disease and Chondrocalcinosis, sponsored by Istituto Ortopedico Rizzoli. Not yet recruiting at 2 sites in Italy. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Istituto Ortopedico Rizzoli · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Arthritis, Rheumatoid with a site in Italy — 19 open to participants now, 29 under way, 3 of them phase 3. Arthritis, Rheumatoid · Italy.
Among the 188 studies in Arthritis, Rheumatoid with a site in Italy, this one is the 110th largest by planned enrollment of the 145 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, reaches primary completion later than 22 of the 28 other live ones, and was the 189th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →19 of the 188 studies in Arthritis, Rheumatoid with a site in Italy are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 8 more countries
Ages 18–65
Philogen S.p.A. · Sites in Italy
Ages 18–80
Merck Sharp & Dohme LLC · Sites in Italy, Australia, Belgium and 8 more countries
Ages 18–75
GlaxoSmithKline · Sites in Italy, Argentina, Brazil and 6 more countries
Ages 18–70
Hoffmann-La Roche · Sites in Italy, United States, Argentina and 9 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 40 · Phase 3 69 · Phase 4 21
First in 2000; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 323 across the 145 interventional studies, 255 across the 43 observational. Of the 150 that completed or were terminated, 106 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
161 of 188 have an industry lead sponsor. The 10 most frequent:
Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.
Istituto Ortopedico Rizzoli has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
3 of the studies in Arthritis, Rheumatoid with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137598Hoffmann-La RocheA Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | 2027-04-17 |
| NCT07680101Universita di VeronaIntra-Articular Adelmidrol 2%/Hyaluronic Acid 1% With or Without m/umPEA, in Knee Pain Due to Joint Degeneration. | 2027-06 |
| NCT02038140Zimmer BiometZimmer Trabecular Metal Total Ankle PMCF | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 188 studies in Arthritis, Rheumatoid with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if a high-resolution computed tomography scan (HR-pQCT) can detect and describe calcium crystal deposits in the hands and wrists of adults with rheumatoid arthritis (RA). The main questions it aims to answer are:
During a single clinic visit, participants will:
Calcium pyrophosphate deposition (CPPD) disease is an underdiagnosed crystal arthritis that frequently mimics rheumatoid arthritis (RA) or coexists with it, particularly when presenting as chronic inflammatory polyarthritis involving the wrists and metacarpophalangeal (MCP) joints. Although synovial fluid crystal identification remains the reference standard, aspiration of small hand joints is often technically unfeasible or non-diagnostic. Consequently, diagnosis relies heavily on conventional radiography and musculoskeletal ultrasonography, both of which suffer from recognized limitations in detecting subtle or early calcifications.
High-resolution peripheral quantitative computed tomography (HR-pQCT) provides superior spatial resolution and volumetric bone microarchitecture assessment. This multicenter, cross-sectional pilot study investigates whether HR-pQCT can enhance the detection and structural characterization of CPPD-suggestive calcium deposits within the triangular fibrocartilage complex (TFCC) and 2nd/3rd MCP hyaline cartilage.
To enable combined multi-site analysis, cross-calibration between the two participating tertiary centers (IRCCS Istituto Ortopedico Rizzoli, utilizing a second-generation Scanco XtremeCT II system, and AOUI Verona, utilizing a RAR Medical Devices ArtiCAT cone-beam system) is conducted using the European Forearm Phantom (EFP; QRM AG). Scans follow harmonized volumetric acquisition protocols based on international recommendations (SPECTRA group). All imaging acquisitions (radiographs, ultrasound, and HR-pQCT) are evaluated independently and in a double-blinded manner by trained musculoskeletal radiologists and rheumatologists.
At the patient level, a participant is classified as positive if at least one calcium deposit is detected in any of the examined joints. Because each participant undergoes imaging across multiple anatomical sites (the TFCC of the wrist and the 2nd and 3rd metacarpophalangeal joints of both hands), observations from the same individual are correlated. To account for this within-subject correlation without losing anatomical detail, site-specific analyses will be conducted using mixed-effects models or generalized estimating equations (GEE).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Rheumatoid Arthritis (RA) Cohort:
Calcium Pyrophosphate Deposition (CPPD) Cohort:
Control Cohort (Non-inflammatory Controls):
Exclusion Criteria:
All Cohorts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with RA and current or prior hand/wrist involvement (n = 60).
Device: High-Resolution peripheral Quantitative Computed Tomography Imaging
Subjects undergoing hand/wrist imaging for non-inflammatory conditions (n = 60).
Device: High-Resolution peripheral Quantitative Computed Tomography Imaging
Patients with proven CPPD disease (n = 20).
Device: High-Resolution peripheral Quantitative Computed Tomography Imaging
High-Resolution peripheral Quantitative Computed Tomography imaging of the 2nd and 3rd metacarpophalangeal joints and triangular fibrocartilage complex (TFCC) of the wrist. Conventional radiography (CR) and ultrasonography (US) serve as baseline standard-of-care comparator modalities performed during routine clinical practice.
Also known as: HR-pQCT, Scanco XtremeCT II, RAR Medical Devices ArtiCAT cone-beam
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in rheumatoid arthritis
Percentage of participants with rheumatoid arthritis with at least one calcium deposit suggestive of CPPD detected by HR-pQCT at the triangular fibrocartilage complex (TFCC) and/or the 2nd-3rd metacarpophalangeal (MCP) joints.
Time frame: Baseline (single imaging visit)
Proportion of HR-pQCT-positive cases missed by conventional imaging
Percentage of participants with no CPPD-suggestive calcium deposits on either conventional radiography or ultrasonography who have at least one CPPD-suggestive calcium deposit on HR-pQCT.
Time frame: Baseline (single imaging visit)
Agreement between conventional radiography and HR-pQCT for CPPD-suggestive calcium deposits
Cohen's kappa coefficient for agreement between conventional radiography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.
Time frame: Baseline (single imaging visit)
Agreement between ultrasonography and HR-pQCT for CPPD-suggestive calcium deposits
Cohen's kappa coefficient for agreement between ultrasonography and HR-pQCT in classifying participants as positive or negative for CPPD-suggestive calcium deposits.
Time frame: Baseline (single imaging visit)
Agreement between combined conventional imaging and HR-pQCT for CPPD-suggestive calcium deposits
Cohen's kappa coefficient for agreement between combined conventional imaging and HR-pQCT. A participant is classified as positive on combined conventional imaging if deposits are detected on radiography, ultrasonography, or both.
Time frame: Baseline (single imaging visit)
Volume of CPPD-suggestive calcium deposits on HR-pQCT
Total volume of CPPD-suggestive calcium deposits per participant, measured on HR-pQCT (mm³), in participants with at least one deposit.
Time frame: Baseline (single imaging visit)
Volumetric density of CPPD-suggestive calcium deposits on HR-pQCT
Mean volumetric density of CPPD-suggestive calcium deposits (mg HA/cm³), measured on HR-pQCT, in participants with at least one deposit.
Time frame: Baseline (single imaging visit)
Anatomical distribution of CPPD-suggestive calcium deposits on HR-pQCT
Percentage of participants with deposits at the TFCC only, at the 2nd-3rd MCP joints only, or at both sites, among participants with at least one deposit on HR-pQCT.
Time frame: Baseline (single imaging visit)
Prevalence of CPPD-suggestive calcium deposits on HR-pQCT in seronegative vs seropositive rheumatoid arthritis
Percentage of participants with at least one CPPD-suggestive calcium deposit on HR-pQCT, reported separately for seronegative participants (RF- and ACPA-negative) and seropositive participants.
Time frame: Baseline (single imaging visit)
Plan to share: No
Start is estimated for Jan 2027; primary completion for Apr 2029, 27 months later.
Of 292 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 27 months is above that.
Counting every sponsor, half of 348 studies reached it within 27 months; a quarter within 13 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.